A 13-year-old girl in Canada and a senior in Louisiana have been among the latest to suffer severe cases of H5N1, or bird flu, raising concerns over the virus’s potential to spark a pandemic. As the virus continues to spread, experts are focusing on how to combat it, particularly through vaccines.
Dr. William Schaffner, a professor at Vanderbilt University Medical Center and spokesperson for the Infectious Disease Society of America, emphasized the global concern, stating, “The worry is that H5N1 could acquire mutations that would allow it to infect human cells and spread widely, opening the door to a new pandemic.” For this to happen, the virus would need to undergo mutations, which could potentially occur if someone were infected with both H5N1 and seasonal flu, allowing for genetic recombination.
Although this mutation has not yet occurred, health authorities are actively working on vaccines to prepare for such an event. U.S. Centers for Disease Control and Prevention (CDC) Director Dr. Mandy Cohen has expressed support for using mRNA technology for bird flu vaccines due to its ability to produce and distribute vaccines quickly. Several vaccines targeting H5N1 have already been developed, and the U.S. government holds doses in its national stockpile. While these vaccines are based on older H5N1 strains, health officials are hopeful they would offer protection against the current circulating virus.
Health officials from the National Institute on Allergy and Infectious Diseases (NIAID) reported that the vaccines showed effectiveness in neutralizing circulating H5N1 strains in laboratory tests, though clinical trials on humans are still needed.
Moderna, Pfizer, and GlaxoSmithKline, in collaboration with CureVac, are currently working on mRNA-based vaccines for H5N1. The U.S. government awarded Moderna $176 million to develop its version. Initial tests in animals, such as ferrets, have shown promising results, with vaccinated animals surviving lethal doses of the virus. The flexibility of mRNA technology is one of its key advantages, allowing for rapid updates to the vaccine if the virus mutates.
Though mRNA vaccines could be developed within months, testing them in clinical trials would take longer. Experts, like Scott Hensley from the University of Pennsylvania, advocate for large-scale pre-pandemic trials to ensure vaccines can be deployed quickly if needed.
In addition to H5N1-specific vaccines, Hensley has worked on a broadly targeted flu vaccine that could protect against a range of influenza strains, including H5N1. This vaccine showed promise in animal tests, reducing illness severity even when exposed to different variants.
Currently, the CDC does not recommend the general public receive the H5N1 vaccine, as the risk remains low. However, individuals in high-risk occupations, such as those working with poultry or livestock, may benefit from vaccination, as seen in Finland, which offers a bird flu vaccine to certain workers. As H5N1 continues to pose a threat, experts remain vigilant, continuing to develop strategies to mitigate the risk of a global outbreak.
